Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.
Study designOther primary literature
SubjectHuman
Record checks
- Study design
- Other primary literature
- Subject
- Human
- Publication year
- 2020
- Source
- doi.org
- Abstract display
- Not reproduced here
- Publication status
- Active
- Status checked
- 17 Aug 2026
- Collected
- 3 Aug 2026
- Freshness
- Current
- Review stage
- Automated
- Record status
- Published
Abstract
cc by 以外（cc by-nc / cc by-nc-nd / NONE 等）は抄録を再掲しない。DOI/PMID へのリンクのみ表示する。
MeSH
DOI 10.1002/jhbp.821
PMID 32894808
View source →